Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d’Athérosclérose (NSFA) - Durlach, Vincent; Bonnefont-Rousselot, Dominique; Boccara, Franck; Varret, Mathilde; Di-Filippo Charcosset, Mathilde; Cariou, Bertrand; Valero, René; Charriere, Sybil; Farnier, Michel; Morange, Pierre E.; Meilhac, Olivier; Lambert, Gilles; et al. (Archives of cardiovascular diseases, 2021)
Keywords: Apolipoprotein(a); Atherosclerosis; Atherothrombosis; Athérosclérose; Biochemistry, Molecular Biology; Calcification de la valve aortique; Cardiovascular diseases; Cardiovascular Diseases / diagnosis; Cardiovascular Diseases / epidemiology; Consensus; Humans; Life Sciences; Lipoprotein(a); Lipoprotéine(a); Lipoprotéines (LDL); Maladies cardiovasculaires; Plasminogen; Plasminogène; Risk Factors; CETP; Apolipoprotein(a); GWAS; RNA; VTE; Athérosclérose; PCSK9; HR; Maladies cardiovasculaires; KIV2-CNV; Lp(a); Lipoprotein(a); apo(a); SNP; LDL; Lipoprotéine(a); Lipoprotéines (LDL); LOE/Class; ASO; LDLR; OxPL; Plasminogène; CI; Calcification de la valve aortique; Atherothrombosis; CVD; PAD; Plasminogen; Cardiovascular diseases; AVS; CHD